3-indomethacinoxyiminoolean-12-en-28-oic acid morpholide

3-indomethacinoxyiminoolean-12-en-28-oic acid morpholide is a synthetic small molecule conjugate that combines the nonsteroidal anti-inflammatory drug (NSAID) indomethacin with a morpholide derivative of oleanolic acid oxime. Developed by researchers at the Poznan University of Medical Sciences, this compound is designed to enhance the anti-inflammatory and anti-tumorigenic effects of its parent molecules while potentially mitigating the side effects associated with long-term NSAID use. It functions as a dual inhibitor of the Nrf2-ARE and NF-κB signaling pathways. In preclinical models of pancreatic cancer, the compound has been shown to decrease the nuclear accumulation and DNA binding of Nrf2, NF-κB p50, and NF-κB p65, leading to the downregulation of downstream targets such as cyclooxygenase-2 (COX-2) and superoxide dismutase 1 (SOD-1). This mechanism suggests its potential as a chemopreventive agent or a modulator to overcome chemoresistance in pancreatic and hepatocellular carcinomas.

Other names

oleanolic acid oxime-indomethacin morpholide conjugateOAO-IND morpholide